Johnson & Johnson
Leads the global phase 3 trial of NBTXR3, the radiotherapy-boosting nanoparticles it licensed from Nanobiotix.
Nanobiotix, 24 Sept 2026Prices by TradingView, about 15 minutes delayed. Not investment advice.
- Ticker
- JNJ · NYSE
- Based in
- United States
- Website
- jnj.com ↗
How nano is it?
No filing of theirs says yet
We flag how much of a business is nanotechnology only when the company's own filings say it. Until then we describe what it makes.
What we track
Its technologies, and how far each has got
On the record
Latest steps
The newest dated events on the technologies above.
- Human trialCompany-reported
NBTXR3
Nanobiotix reported that the FDA had cleared changes to the Johnson & Johnson-led phase 3 trial in head and neck cancer, NANORAY-312, so that its final analysis can come sooner.
Nanobiotix, 24 Sept 2026 - Funding or dealCompany-reported
NBTXR3
Nanobiotix licensed NBTXR3 to Janssen, a Johnson & Johnson company, for development and sale worldwide.
Nanobiotix, 24 Sept 2026 - ApprovalCompany-reported
NBTXR3
Nanobiotix said its product, sold under the name Hensify, won a CE mark in Europe for locally advanced soft tissue sarcoma.
Nanobiotix via BioSpace, 4 Apr 2019
Not investment advice. We describe what companies do and what their own filings say; we never say whether to buy or sell.